JMP Securities Reiterates Market Outperform on Haemonetics, Maintains $125 Price Target
Portfolio Pulse from Benzinga Newsdesk
JMP Securities analyst David Turkaly has reiterated a Market Outperform rating on Haemonetics (NYSE:HAE) and maintained a price target of $125.
August 13, 2024 | 6:41 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
JMP Securities analyst David Turkaly has reiterated a Market Outperform rating on Haemonetics (NYSE:HAE) and maintained a price target of $125.
The reiteration of a Market Outperform rating and the maintenance of a $125 price target by JMP Securities is a positive signal for investors. It suggests confidence in Haemonetics' future performance, likely leading to a short-term positive impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100